And we know the bankruptcy judge had approved of Taran providing $1M in financing, ahead of the closing of the bankruptcy, when they paid an additional $1M.
So we could have about $4M of additional lenz either produced, or scheduled to be produced. Starting a revenue stream is a required objective for Humanigen/Taran, and with Durrant investing millions into the operation at this point, I don't see why I should be worried, if he isn't.
The frenemies who, along with the FDA, kept us out of the market, are themselves now financially threatened. People are waking up to the harm inflicted by the mRNA vaccines. That is resulting in substantial revenue declines for Pfizer and Moderna, and steep cuts in FDA funding operations from Big Pharma, including licensing fees required of Big Pharma to the FDA.
If we get Novavax to use lenz under the approved IND authorization, to enhance the efficacy their vaccine with our patented formulation, we will own the covid market. Investors will be clamoring to buy shares, and Humanigen owns ~90% of the Outstanding Shares. But prospective buyers will have to compete with brokerages who will be faced with a recall of the loaned shares.
And that is just looking at the covid scenario, which seems more likely than ever, and much larger than ever. We also know that CMML treatment approval looks likely in Australia.
Taran can do nothing to meet the demand for shares.
News 
Market Data 
Discover 
AI
